ArticleDrug target insights
Antioxidant potential of a new macrocyclic bisbibenzyl and other compounds from
Article in Drug target insights. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Free radicals are key contributors to several diseases, including cancer, inflammation, pain, and neurodegenerative disorders such as Alzheimer's disease. Due to the limitations and adverse effects of synthetic antioxidants, naturally occurring phytochemicals offer safer, more sustainable alternatives. This study investigates the antioxidant potential of twigs of Methods: Compounds were isolated using chromatographic methods, and their structures established by 1D- and 2D-NMR, HR-ESI-MS, and comparison with reported data. Antioxidant activity was assessed through DPPH radical scavenging and FRAP assays, while molecular docking against xanthine oxidase (PDB: 1FIQ) explored possible mechanisms beyond direct radical scavenging. Results: A new macrocyclic bisbibenzyl derivative, combrebisbibenzyl A ( Conclusion: These findings support the traditional use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.